Qiagen NV (LTS:0RLT)
€ 43.54 0 (0%) Market Cap: 9.16 Bil Enterprise Value: 9.58 Bil PE Ratio: 106.36 PB Ratio: 2.73 GF Score: 85/100

Qiagen NV at Jefferies Healthcare Conference (Virtual) Transcript

Jun 02, 2021 / 01:00PM GMT
Release Date Price: €39.79 (-2.19%)
Peter James Welford
Jefferies LLC, Research Division - Senior Equity Analyst & European Pharmaceuticals Analyst

Good morning, and good afternoon to those of you joining us from Europe. My name is Peter Welford. I'm the European pharma and biotech and life sciences analyst at Jefferies in London.

It's my great pleasure to introduce the next company in this track, which is QIAGEN. And it's our great pleasure to have here to join us today the CEO, Thierry Bernard. He's going to talk us through a few brief moments of introduction, and then we'll go straight into the fireside chat.

And with that, I'll pass over to Thierry, and thank you very much for joining us. Thank you.

Thierry Bernard
QIAGEN N.V. - CEO, MD & Member of Management Board

No, thanks for having me, Peter, and good morning, good afternoon to everybody on the line, and thanks for the interest in QIAGEN.

Just in a few words, you have seen our earnings calls a couple of weeks ago. So what is of deep satisfaction for us as management of QIAGEN is that, first of all,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot